Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,720,000 shares, an increase of 13.2% from the December 15th total of 1,520,000 shares. Based on an average trading volume of 773,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 5.2% of the company's shares are sold short.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Walleye Capital LLC increased its position in shares of Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company's stock valued at $231,000 after acquiring an additional 10,528 shares during the period. American Century Companies Inc. increased its holdings in Werewolf Therapeutics by 50.7% during the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock valued at $92,000 after purchasing an additional 12,656 shares during the period. SG Americas Securities LLC bought a new position in Werewolf Therapeutics during the 3rd quarter valued at approximately $29,000. Point72 DIFC Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $34,000. Finally, XTX Topco Ltd purchased a new stake in Werewolf Therapeutics in the 3rd quarter worth approximately $45,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on HOWL. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities cut their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday, January 14th.

Werewolf Therapeutics Stock Performance

HOWL stock traded down $0.01 during midday trading on Friday, hitting $1.33. The company had a trading volume of 179,090 shares, compared to its average volume of 273,803. Werewolf Therapeutics has a 52 week low of $1.31 and a 52 week high of $8.19. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock's 50 day moving average price is $1.69 and its 200 day moving average price is $2.09.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.